AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Positive opinions based on significant survival benefit
Subscribe To Our Newsletter & Stay Updated